SO THE SO CALLED 'INDEPENDENT' article published yesterday is not so independent !!! Dr. Fisher is going to be biased. Aonther one of the pumps by Messling.
 They will not start phase 2/3 till they get more 12 month data from 2a. They made that clear. So don't expect any news of enrollment for 2/3 till mid 2016 MINIMUM.
 There is going to be NO partnership, despite the hype of the pumpers. No partner is going to put money in a company with only phase 2a.
 Dilution is coming that is for sure. Either thru stock dilution or selling to Lincoln.
 Unfortunately AF is right.....Japanese company already did sigma -1 AZ, and it failed. Pumpers are saying chemical composition is different, but this puts AVXL at VERY HIGH RISK.
 The company is putting positive spin on interim results...but it is such small N, off and on, this is really bad. Something is not right. If PRAN can do placebo in 2A, why didn't AVXL.
 Management is definitely pumping...too similar to pump for PRAN, and the Japanese drug. Same doctor said the SAME pump for PRAN.
Guys this is NO miracle drug...sorry to burst your bubble.
we should be AT LEAST $500- $800 MILLION market cap. FDA obviously does not think this is a fraud.
hey pumpers, there is NO new set of data due in December...they are going to present Eplipsy preclinical data, which they already published earlier this year. There is nothing new happening here. Not sure what folks are expecting in December.
I would really question the CEO here...why did he work his news release so that it appears that FDA approved phase 2/3 ?? I think there is bit of pumping by CEO when he saw the stock tank so much.
Stock has historically never been this cheap. Amazing.
wow imhojustsayin why do you need to respond to EVERY post on this board ??? Do you even have a job ??
dude the entire market is going down...look at horizon, all other bios. People somehow feel if oil crashes, people will buy less pain medication !!
Low volume selloffs in a good sign. Wait for earnings and see. CEO was very bullish to reject $33 offer because he knows stock is undervalued. He is looking longer term. Obviously Horizon saw big value in DEPO long term to offer $33.
AND ignore the fool imhojustsayin...he thinks EVERY phase 1/2/3 biotech should be worth 0, because they have no revenue !!
it does not compute because a penny stock most likely 99.9% does not have cure of ALZ...when huge multi billion dollar bio companies have not been able to find a better treatment.
If it was such great science why hasn't someone just bought them out at such low price ???
Its going to cost much more than what they have in the back.. Selling to Lincoln will be DILUTION.
it UNDERVALUES the value of the company...the CEO is definitely very bullish for 2016. buy low.
acquisition news ?
big selloff tomorrow.
wow apple9999 how much money do you want in this POS ??? WHAT A PUMPER ! Having PHDs does not mean the drug works !!! Keep praying for a partnership.
He is also the inventor of AF710B (renamed ANAVEX 3-71), the unique and promising preclinical Alzheimer?s drug candidate for which we recently obtained exclusive worldwide rights.
BIASED, no ???? He is pumping his own invention. INDEPENDENT RESEARCH MY #$%$ !!
TOTALLY agree. It was misleading news...FDA did not give them guidance for 2/3....it as rehashed PR.
of his scientific board doing it for him.
Yesterday's news was total BS....Inventor of the product says it is a great product. That is total pumping.
go to SA and read Dr. Kline response to Kanti article.
The drug is no better than DPZ....That is the bottom line.
They are doing a very small selective patient group, on and off treatment for 32 days, maybe included some high doses of coffee in there (who knows?). Just to get on NAZ and pump up the shares. This is some serious pump and dump guys. Go read the comments from PRAN ph 2 from the same doctor in Austrialia...SAYS THE SAME THING ABOUT PRAN !!! Miracle drug....
Be very careful.
hope longs took profit at 8. maybe they got confused between 273 and 271.
nothing changed....CEO extremely bullish last call...plus even said $33 share takeout UNDERVALUES potential...with stock 35% down since last earnings, no bad news, think good time to go long into earnings.